Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple sclerosis clinical trials: old and new challenges

J H Noseworthy1

  • 1Department of Neurology, Mayo Clinic/Mayo Foundation, Rochester, Minnesota 55905, USA.

Seminars in Neurology
|November 17, 1998
PubMed
Summary

Multiple sclerosis (MS) treatments show partial effectiveness, changing clinical trial research. Further methodological revisions are needed to identify beneficial agents and remove ineffective or toxic ones.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disability as an outcome in MS clinical trials.

Neurology·2008
Same author

A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis.

Neurology·2005
Same author

Disability profile of MS did not change over 10 years in a population-based prevalence cohort.

Neurology·2004
Same author

Change in MS-related disability in a population-based cohort: a 10-year follow-up study.

Neurology·2004
Same author

Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000.

Neurology·2003
Same author

International consensus statement on the use of disease-modifying agents in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2002

Area of Science:

  • Neurology
  • Clinical Research Methodology

Background:

  • Multiple sclerosis (MS) treatment landscape has evolved with agents showing partial effectiveness.
  • Recent clinical trials support the positive short-term impact of various MS therapies.

Purpose of the Study:

  • To review current trends in multiple sclerosis clinical trial research.
  • To suggest methodological revisions for efficient identification of effective MS treatments.

Main Methods:

  • Review of recently published clinical trials in relapsing-remitting multiple sclerosis.
  • Analysis of agent efficacy and toxicity data from Phase III trials.

Main Results:

  • Several agents demonstrate partial effectiveness in managing relapsing-remitting MS.
  • Some promising agents have proven ineffective or too toxic for broad application.
  • Unconfirmed positive trial results create guarded optimism.

Conclusions:

  • Current MS trial methodologies require revision to expedite the discovery of beneficial treatments.
  • Refined methods are essential to eliminate non-beneficial or toxic agents from consideration.

Related Experiment Videos